Axitinib

SAN FRANCISCO — Axitinib combined with nivolumab demonstrated encouraging efficacy among treatment-naive patients with metastatic renal cell carcinoma, according to study results presented at ASCO Genitourinary Cancers Symposium.

Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for advanced clear cell renal cell carcinoma, according to long-term follow-up of the randomized phase 3 KEYNOTE-426 trial.

OTX-TKI, a hydrogel-based implant in development for sustained-release delivery of axitinib, has been well tolerated in patients with neovascular age-related macular degeneration, according to a study.

Adjuvant pembrolizumab prolonged DFS compared with placebo for patients with renal cell carcinoma who underwent nephrectomy with or without resection of metastatic lesions, according to the agent’s manufacturer.

The first patients have been enrolled in a phase 1/2a clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration, according to a press release from Clearside Biomedical.

Axitinib significantly extended PFS among patients with recurred or metastatic adenoid cystic carcinoma, according to results of a randomized phase 2 study presented during the ASCO20 Virtual Scientific Program.